SCHEMBL5955997

SCHEMBL5955997

COc1ccc(Oc2ccc(N)c(NS(=O)(=O)c3ccc4ccccc4c3)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
PGR P06401 2/20 0.56
KEAP1 Q14145 4/20 0.56
TDP1 Q9NUW8 2/20 0.56
POLB P06746 1/20 0.56
CKS1B P61024 1/20 0.51
SKP2 Q13309 1/20 0.51
NFE2L2 Q16236 2/20 0.50
SQSTM1 Q13501 1/20 0.50
AGTR1 P30556 1/20 0.50
PLAU P00749 4/20 0.49
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49
ST14 Q9Y5Y6 1/20 0.49
PLA2G7 Q13093 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5955992 0.84 CYP2C9 (0.55) MEN1KMT2APGRKEAP1TDP1
SCHEMBL5956030 0.84 FFAR4 (0.60) MEN1KMT2APGRKEAP1TDP1
SCHEMBL5955965 0.81 PGR (0.56) PGRKEAP1NFE2L2SQSTM1
SCHEMBL9927442 0.79 KMT2A (0.78) MEN1KMT2ATDP1POLBAGTR1
SCHEMBL8752432 0.78 PLAU (0.76) MEN1KMT2APGRPLAUMAPT
SCHEMBL5955308 0.77 PGR (0.70) KMT2APGRKEAP1NFE2L2SQSTM1
SCHEMBL6560643 0.76 KEAP1 (0.70) KMT2APGRKEAP1POLBNFE2L2
SCHEMBL5956219 0.76 KEAP1 (0.63) KMT2APGRKEAP1CKS1BSKP2
SCHEMBL5955460 0.76 PGR (0.65) PGRKEAP1NFE2L2SQSTM1MAPT
SCHEMBL5956173 0.74 FFAR4 (0.64) PGRKEAP1CKS1BSKP2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006014405-A2 SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-02-09 WO claimed
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2006-01-05 US claimed
WO-2006014405-A2 SULFONAMIDE-BASED COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-02-09 WO disclosed
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004197-A1 Sulfonamide-based compounds as protein tyrosine kinase inhibitors SRC, LCK, ABL1 MEN1 2537/4885KMT2A 324/4885PGR 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.